Clinical Trial Update: Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating a multi-phosphopeptide vaccine in combination with the adjuvant PolyICLC in melanoma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Multi-phosphopeptide vaccine (multi-phosphopeptide vaccine)
• PolyICLC (poly-ICLC)

Snippet

Sponsor: Craig L Slingluff, Jr | Conditions: Melanoma | Phase 1 | Status: COMPLETED